<?xml version="1.0" encoding="utf-8"?>
<Return xmlns="http://www.irs.gov/efile" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.irs.gov/efile" returnVersion="2022v5.0">
  <ReturnHeader binaryAttachmentCnt="0">
    <ReturnTs>2023-05-08T11:58:11-05:00</ReturnTs>
    <TaxPeriodEndDt>2022-12-31</TaxPeriodEndDt>
    <PreparerFirmGrp>
      <PreparerFirmEIN>233018514</PreparerFirmEIN>
      <PreparerFirmName>
        <BusinessNameLine1Txt>DUNLAPSLK PC</BusinessNameLine1Txt>
      </PreparerFirmName>
      <PreparerUSAddress>
        <AddressLine1Txt>1300 HORIZON DRIVE SUITE 106</AddressLine1Txt>
        <CityNm>CHALFONT</CityNm>
        <StateAbbreviationCd>PA</StateAbbreviationCd>
        <ZIPCd>18914</ZIPCd>
      </PreparerUSAddress>
    </PreparerFirmGrp>
    <ReturnTypeCd>990</ReturnTypeCd>
    <TaxPeriodBeginDt>2022-01-01</TaxPeriodBeginDt>
    <Filer>
      <EIN>232740843</EIN>
      <BusinessName>
        <BusinessNameLine1Txt>ALTERNATIVES RESEARCH AND DEVELOPMENT FO</BusinessNameLine1Txt>
      </BusinessName>
      <BusinessNameControlTxt>ALTE</BusinessNameControlTxt>
      <PhoneNum>2158878076</PhoneNum>
      <USAddress>
        <AddressLine1Txt>801 OLD YORK ROAD 218</AddressLine1Txt>
        <CityNm>JENKINTOWN</CityNm>
        <StateAbbreviationCd>PA</StateAbbreviationCd>
        <ZIPCd>19046</ZIPCd>
      </USAddress>
    </Filer>
    <BusinessOfficerGrp>
      <PersonNm>SUE A LEARY</PersonNm>
      <PersonTitleTxt>PRESIDENT</PersonTitleTxt>
      <PhoneNum>2158878076</PhoneNum>
      <SignatureDt>2023-05-04</SignatureDt>
      <DiscussWithPaidPreparerInd>1</DiscussWithPaidPreparerInd>
    </BusinessOfficerGrp>
    <SigningOfficerGrp>
      <PersonFullName>
        <PersonFirstNm>SUE</PersonFirstNm>
        <PersonLastNm>LEARY</PersonLastNm>
      </PersonFullName>
      <SSN>999009999</SSN>
    </SigningOfficerGrp>
    <IRSResponsiblePrtyInfoCurrInd>0</IRSResponsiblePrtyInfoCurrInd>
    <PreparerPersonGrp>
      <PreparerPersonNm>JULIA L DAVIS</PreparerPersonNm>
      <PTIN>P00163568</PTIN>
      <PhoneNum>2675943755</PhoneNum>
      <PreparationDt>2023-05-04</PreparationDt>
    </PreparerPersonGrp>
    <AdditionalFilerInformation>
      <TrustedCustomerGrp>
        <TrustedCustomerCd>0</TrustedCustomerCd>
        <AuthenticationAssuranceLevelCd>AAL1</AuthenticationAssuranceLevelCd>
        <IdentityAssuranceLevelCd>IAL1</IdentityAssuranceLevelCd>
      </TrustedCustomerGrp>
    </AdditionalFilerInformation>
    <TaxYr>2022</TaxYr>
    <BuildTS>2023-04-26 12:10:37Z</BuildTS>
  </ReturnHeader>
  <ReturnData documentCnt="10">
    <IRS990 documentId="RetDoc1038000001" referenceDocumentId="RetDoc1044400001">
      <PrincipalOfficerNm>SUE A LEARY</PrincipalOfficerNm>
      <USAddress>
        <AddressLine1Txt>801 OLD YORK ROAD 218</AddressLine1Txt>
        <CityNm>JENKINTOWN</CityNm>
        <StateAbbreviationCd>PA</StateAbbreviationCd>
        <ZIPCd>19046</ZIPCd>
      </USAddress>
      <GrossReceiptsAmt>2873045</GrossReceiptsAmt>
      <GroupReturnForAffiliatesInd>0</GroupReturnForAffiliatesInd>
      <Organization501c3Ind>X</Organization501c3Ind>
      <WebsiteAddressTxt>WWW.ARDF-ONLINE.ORG</WebsiteAddressTxt>
      <TypeOfOrganizationCorpInd>X</TypeOfOrganizationCorpInd>
      <FormationYr>1993</FormationYr>
      <LegalDomicileStateCd>PA</LegalDomicileStateCd>
      <ActivityOrMissionDesc>ARDF PROMOTES AND DEVELOPS ALTERNATIVE SCIENTIFIC SOLUTIONS TO THE PROBLEM OF ANIMAL TESTING.</ActivityOrMissionDesc>
      <VotingMembersGoverningBodyCnt>7</VotingMembersGoverningBodyCnt>
      <VotingMembersIndependentCnt>6</VotingMembersIndependentCnt>
      <TotalEmployeeCnt>1</TotalEmployeeCnt>
      <TotalVolunteersCnt>10</TotalVolunteersCnt>
      <TotalGrossUBIAmt>0</TotalGrossUBIAmt>
      <NetUnrelatedBusTxblIncmAmt>0</NetUnrelatedBusTxblIncmAmt>
      <PYContributionsGrantsAmt>69409</PYContributionsGrantsAmt>
      <CYContributionsGrantsAmt>333654</CYContributionsGrantsAmt>
      <PYProgramServiceRevenueAmt>0</PYProgramServiceRevenueAmt>
      <CYProgramServiceRevenueAmt>0</CYProgramServiceRevenueAmt>
      <PYInvestmentIncomeAmt>1506279</PYInvestmentIncomeAmt>
      <CYInvestmentIncomeAmt>526141</CYInvestmentIncomeAmt>
      <PYOtherRevenueAmt>8505</PYOtherRevenueAmt>
      <CYOtherRevenueAmt>0</CYOtherRevenueAmt>
      <PYTotalRevenueAmt>1584193</PYTotalRevenueAmt>
      <CYTotalRevenueAmt>859795</CYTotalRevenueAmt>
      <PYGrantsAndSimilarPaidAmt>285938</PYGrantsAndSimilarPaidAmt>
      <CYGrantsAndSimilarPaidAmt>270142</CYGrantsAndSimilarPaidAmt>
      <PYBenefitsPaidToMembersAmt>0</PYBenefitsPaidToMembersAmt>
      <CYBenefitsPaidToMembersAmt>0</CYBenefitsPaidToMembersAmt>
      <PYSalariesCompEmpBnftPaidAmt>42124</PYSalariesCompEmpBnftPaidAmt>
      <CYSalariesCompEmpBnftPaidAmt>45870</CYSalariesCompEmpBnftPaidAmt>
      <PYTotalProfFndrsngExpnsAmt>0</PYTotalProfFndrsngExpnsAmt>
      <CYTotalProfFndrsngExpnsAmt>0</CYTotalProfFndrsngExpnsAmt>
      <CYTotalFundraisingExpenseAmt>3260</CYTotalFundraisingExpenseAmt>
      <PYOtherExpensesAmt>212315</PYOtherExpensesAmt>
      <CYOtherExpensesAmt>265256</CYOtherExpensesAmt>
      <PYTotalExpensesAmt>540377</PYTotalExpensesAmt>
      <CYTotalExpensesAmt>581268</CYTotalExpensesAmt>
      <PYRevenuesLessExpensesAmt>1043816</PYRevenuesLessExpensesAmt>
      <CYRevenuesLessExpensesAmt>278527</CYRevenuesLessExpensesAmt>
      <TotalAssetsBOYAmt>15528574</TotalAssetsBOYAmt>
      <TotalAssetsEOYAmt>11875792</TotalAssetsEOYAmt>
      <TotalLiabilitiesBOYAmt>45018</TotalLiabilitiesBOYAmt>
      <TotalLiabilitiesEOYAmt>42464</TotalLiabilitiesEOYAmt>
      <NetAssetsOrFundBalancesBOYAmt>15483556</NetAssetsOrFundBalancesBOYAmt>
      <NetAssetsOrFundBalancesEOYAmt>11833328</NetAssetsOrFundBalancesEOYAmt>
      <InfoInScheduleOPartIIIInd>X</InfoInScheduleOPartIIIInd>
      <MissionDesc>THE MISSION OF THE ARDF IS TO FUND AND PROMOTE THE DEVELOPMENT, VALIDATION AND ADOPTION OF NON-ANIMAL METHODS IN BIOMEDICAL RESEARCH, PRODUCT TESTING, AND EDUCATION.</MissionDesc>
      <SignificantNewProgramSrvcInd>0</SignificantNewProgramSrvcInd>
      <SignificantChangeInd>0</SignificantChangeInd>
      <ExpenseAmt>418113</ExpenseAmt>
      <GrantAmt>270142</GrantAmt>
      <Desc>THE 'ANNUAL OPEN' GRANT PROGRAM FUNDED PROJECTS AT UNIVERSITIES THAT WILL: 1.) DEVELOP A 3D IN VITRO MODEL OF A PEDIATRIC BRAINSTEM TUMOR, 2.) DEVELOP A 3D ORGANOID MODEL TO STUDY SPECIES-SPECIFIC RESPONSES TO ANTI-CANCER DRUGS, 3.) USE 3D BIOPRINTING AND BIOREACTOR GROWTH TO STUDY CELL MOVEMENT BETWEEN TISSUES DURING CANCER TREATMENT FOR CHRONIC LYMPOCYTIC LEUKEMIA, 4.) DEVELOP A "MINI-JOINT ON A CHIP" MODEL FOR OSTEOARTHRITIS RESEARCH, 5.) UTILIZE BIOREACTOR CULTURING TO REPLACE ANIMALS IN ORDER TO CULTIVATE A CRYPTOSPORIDIUM PARASITE FOR CHILDREN'S HEALTH RESEARCH, AND 6.) DEVELOP A COMPUTATIONAL MODEL FOR ENVIRONMENTAL RISK ASSESSMENT OF DIFFERENT SPECIES. TAKEN TOGETHER, THESE PROJECTS WILL ADVANCE ANIMAL WELFARE AND HUMAN HEALTH.ARDF ALSO SPONSORED SCIENTIFIC MEETINGS, AND EDUCATION AND OUTREACH ON ALTERNATIVE METHODS TO ACCELERATE UNDERSTANDING AND COLLABORATION.</Desc>
      <TotalProgramServiceExpensesAmt>418113</TotalProgramServiceExpensesAmt>
      <DescribedInSection501c3Ind referenceDocumentId="RetDoc1039100001">1</DescribedInSection501c3Ind>
      <ScheduleBRequiredInd referenceDocumentId="RetDoc1234500001">1</ScheduleBRequiredInd>
      <PoliticalCampaignActyInd referenceDocumentId="RetDoc1039600001">0</PoliticalCampaignActyInd>
      <LobbyingActivitiesInd referenceDocumentId="RetDoc1039600001">0</LobbyingActivitiesInd>
      <SubjectToProxyTaxInd referenceDocumentId="RetDoc1039600001">0</SubjectToProxyTaxInd>
      <DonorAdvisedFundInd referenceDocumentId="RetDoc1040000001">0</DonorAdvisedFundInd>
      <ConservationEasementsInd referenceDocumentId="RetDoc1040000001">0</ConservationEasementsInd>
      <CollectionsOfArtInd referenceDocumentId="RetDoc1040000001">0</CollectionsOfArtInd>
      <CreditCounselingInd referenceDocumentId="RetDoc1040000001">0</CreditCounselingInd>
      <DonorRstrOrQuasiEndowmentsInd>1</DonorRstrOrQuasiEndowmentsInd>
      <ReportLandBuildingEquipmentInd referenceDocumentId="RetDoc1040000001">1</ReportLandBuildingEquipmentInd>
      <ReportInvestmentsOtherSecInd referenceDocumentId="RetDoc1040000001">0</ReportInvestmentsOtherSecInd>
      <ReportProgramRelatedInvstInd referenceDocumentId="RetDoc1040000001">0</ReportProgramRelatedInvstInd>
      <ReportOtherAssetsInd referenceDocumentId="RetDoc1040000001">0</ReportOtherAssetsInd>
      <ReportOtherLiabilitiesInd referenceDocumentId="RetDoc1040000001">1</ReportOtherLiabilitiesInd>
      <IncludeFIN48FootnoteInd referenceDocumentId="RetDoc1040000001">1</IncludeFIN48FootnoteInd>
      <IndependentAuditFinclStmtInd referenceDocumentId="RetDoc1040000001">1</IndependentAuditFinclStmtInd>
      <ConsolidatedAuditFinclStmtInd referenceDocumentId="RetDoc1040000001">1</ConsolidatedAuditFinclStmtInd>
      <SchoolOperatingInd>0</SchoolOperatingInd>
      <ForeignOfficeInd>0</ForeignOfficeInd>
      <ForeignActivitiesInd referenceDocumentId="RetDoc1040500001">1</ForeignActivitiesInd>
      <MoreThan5000KToOrgInd referenceDocumentId="RetDoc1040500001">1</MoreThan5000KToOrgInd>
      <MoreThan5000KToIndividualsInd referenceDocumentId="RetDoc1040500001">0</MoreThan5000KToIndividualsInd>
      <ProfessionalFundraisingInd>0</ProfessionalFundraisingInd>
      <FundraisingActivitiesInd>0</FundraisingActivitiesInd>
      <GamingActivitiesInd>0</GamingActivitiesInd>
      <OperateHospitalInd>0</OperateHospitalInd>
      <GrantsToOrganizationsInd referenceDocumentId="RetDoc1041900001">1</GrantsToOrganizationsInd>
      <GrantsToIndividualsInd referenceDocumentId="RetDoc1041900001">0</GrantsToIndividualsInd>
      <ScheduleJRequiredInd>0</ScheduleJRequiredInd>
      <TaxExemptBondsInd>0</TaxExemptBondsInd>
      <EngagedInExcessBenefitTransInd>0</EngagedInExcessBenefitTransInd>
      <PYExcessBenefitTransInd>0</PYExcessBenefitTransInd>
      <LoanOutstandingInd>0</LoanOutstandingInd>
      <GrantToRelatedPersonInd>0</GrantToRelatedPersonInd>
      <BusinessRlnWithOrgMemInd>0</BusinessRlnWithOrgMemInd>
      <BusinessRlnWithFamMemInd>0</BusinessRlnWithFamMemInd>
      <BusinessRlnWith35CtrlEntInd>0</BusinessRlnWith35CtrlEntInd>
      <DeductibleNonCashContriInd>0</DeductibleNonCashContriInd>
      <DeductibleArtContributionInd>0</DeductibleArtContributionInd>
      <TerminateOperationsInd>0</TerminateOperationsInd>
      <PartialLiquidationInd>0</PartialLiquidationInd>
      <DisregardedEntityInd referenceDocumentId="RetDoc1043400001">0</DisregardedEntityInd>
      <RelatedEntityInd referenceDocumentId="RetDoc1043400001">1</RelatedEntityInd>
      <RelatedOrganizationCtrlEntInd>0</RelatedOrganizationCtrlEntInd>
      <TrnsfrExmptNonChrtblRltdOrgInd referenceDocumentId="RetDoc1043400001">0</TrnsfrExmptNonChrtblRltdOrgInd>
      <ActivitiesConductedPrtshpInd referenceDocumentId="RetDoc1043400001">0</ActivitiesConductedPrtshpInd>
      <ScheduleORequiredInd>1</ScheduleORequiredInd>
      <InfoInScheduleOPartVInd>X</InfoInScheduleOPartVInd>
      <IRPDocumentCnt>3</IRPDocumentCnt>
      <IRPDocumentW2GCnt>0</IRPDocumentW2GCnt>
      <EmployeeCnt>1</EmployeeCnt>
      <EmploymentTaxReturnsFiledInd>1</EmploymentTaxReturnsFiledInd>
      <UnrelatedBusIncmOverLimitInd>0</UnrelatedBusIncmOverLimitInd>
      <ForeignFinancialAccountInd>0</ForeignFinancialAccountInd>
      <ProhibitedTaxShelterTransInd>0</ProhibitedTaxShelterTransInd>
      <TaxablePartyNotificationInd>0</TaxablePartyNotificationInd>
      <NondeductibleContributionsInd>0</NondeductibleContributionsInd>
      <QuidProQuoContributionsInd>0</QuidProQuoContributionsInd>
      <Form8282PropertyDisposedOfInd>0</Form8282PropertyDisposedOfInd>
      <RcvFndsToPayPrsnlBnftCntrctInd>0</RcvFndsToPayPrsnlBnftCntrctInd>
      <PayPremiumsPrsnlBnftCntrctInd>0</PayPremiumsPrsnlBnftCntrctInd>
      <IndoorTanningServicesInd>0</IndoorTanningServicesInd>
      <SubjToTaxRmnrtnExPrchtPymtInd>0</SubjToTaxRmnrtnExPrchtPymtInd>
      <SubjectToExcsTaxNetInvstIncInd>0</SubjectToExcsTaxNetInvstIncInd>
      <InfoInScheduleOPartVIInd>X</InfoInScheduleOPartVIInd>
      <GoverningBodyVotingMembersCnt>7</GoverningBodyVotingMembersCnt>
      <IndependentVotingMemberCnt>6</IndependentVotingMemberCnt>
      <FamilyOrBusinessRlnInd>0</FamilyOrBusinessRlnInd>
      <DelegationOfMgmtDutiesInd>0</DelegationOfMgmtDutiesInd>
      <ChangeToOrgDocumentsInd>0</ChangeToOrgDocumentsInd>
      <MaterialDiversionOrMisuseInd>0</MaterialDiversionOrMisuseInd>
      <MembersOrStockholdersInd>0</MembersOrStockholdersInd>
      <ElectionOfBoardMembersInd>0</ElectionOfBoardMembersInd>
      <DecisionsSubjectToApprovaInd>0</DecisionsSubjectToApprovaInd>
      <MinutesOfGoverningBodyInd>1</MinutesOfGoverningBodyInd>
      <MinutesOfCommitteesInd>1</MinutesOfCommitteesInd>
      <OfficerMailingAddressInd>0</OfficerMailingAddressInd>
      <LocalChaptersInd>0</LocalChaptersInd>
      <Form990ProvidedToGvrnBodyInd>1</Form990ProvidedToGvrnBodyInd>
      <ConflictOfInterestPolicyInd>1</ConflictOfInterestPolicyInd>
      <AnnualDisclosureCoveredPrsnInd>1</AnnualDisclosureCoveredPrsnInd>
      <RegularMonitoringEnfrcInd>1</RegularMonitoringEnfrcInd>
      <WhistleblowerPolicyInd>1</WhistleblowerPolicyInd>
      <DocumentRetentionPolicyInd>1</DocumentRetentionPolicyInd>
      <CompensationProcessCEOInd>1</CompensationProcessCEOInd>
      <CompensationProcessOtherInd>0</CompensationProcessOtherInd>
      <InvestmentInJointVentureInd>0</InvestmentInJointVentureInd>
      <StatesWhereCopyOfReturnIsFldCd>PA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MN</StatesWhereCopyOfReturnIsFldCd>
      <OtherWebsiteInd>X</OtherWebsiteInd>
      <UponRequestInd>X</UponRequestInd>
      <BooksInCareOfDetail>
        <BusinessName>
          <BusinessNameLine1Txt>THE ORGANIZATION</BusinessNameLine1Txt>
        </BusinessName>
        <PhoneNum>2158878076</PhoneNum>
        <USAddress>
          <AddressLine1Txt>801 OLD YORK ROAD SUITE 218</AddressLine1Txt>
          <CityNm>JENKINTOWN</CityNm>
          <StateAbbreviationCd>PA</StateAbbreviationCd>
          <ZIPCd>19046</ZIPCd>
        </USAddress>
      </BooksInCareOfDetail>
      <Form990PartVIISectionAGrp>
        <PersonNm>SUE A LEARY</PersonNm>
        <TitleTxt>PRESIDENT</TitleTxt>
        <AverageHoursPerWeekRt>12.00</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>35.00</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>20000</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>59980</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>6011</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>NADIA S ADAWI</PersonNm>
        <TitleTxt>BOARD MEMBER</TitleTxt>
        <AverageHoursPerWeekRt>0.50</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.50</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>ROBERT FINN</PersonNm>
        <TitleTxt>BOARD MEMBER</TitleTxt>
        <AverageHoursPerWeekRt>0.50</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.50</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>FRANCIS KRAFCHIK</PersonNm>
        <TitleTxt>BOARD MEMBER</TitleTxt>
        <AverageHoursPerWeekRt>0.50</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.50</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>JOSEPH LUDWIG</PersonNm>
        <TitleTxt>VICE PRESIDENT</TitleTxt>
        <AverageHoursPerWeekRt>0.50</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>1.00</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>AARON MCINTYRE</PersonNm>
        <TitleTxt>TREASURER</TitleTxt>
        <AverageHoursPerWeekRt>0.50</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>1.00</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>DENISE COWIE</PersonNm>
        <TitleTxt>SECRETARY</TitleTxt>
        <AverageHoursPerWeekRt>0.50</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>1.00</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <TotalReportableCompFromOrgAmt>20000</TotalReportableCompFromOrgAmt>
      <TotReportableCompRltdOrgAmt>59980</TotReportableCompRltdOrgAmt>
      <TotalOtherCompensationAmt>6011</TotalOtherCompensationAmt>
      <IndivRcvdGreaterThan100KCnt>1</IndivRcvdGreaterThan100KCnt>
      <FormerOfcrEmployeesListedInd>0</FormerOfcrEmployeesListedInd>
      <TotalCompGreaterThan150KInd>0</TotalCompGreaterThan150KInd>
      <CompensationFromOtherSrcsInd>0</CompensationFromOtherSrcsInd>
      <ContractorCompensationGrp>
        <ContractorName>
          <BusinessName>
            <BusinessNameLine1Txt>MORGAN STANLEY</BusinessNameLine1Txt>
          </BusinessName>
        </ContractorName>
        <ContractorAddress>
          <USAddress>
            <AddressLine1Txt>1585 BROADWAY</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10036</ZIPCd>
          </USAddress>
        </ContractorAddress>
        <ServicesDesc>INVESTMENT SERVICES</ServicesDesc>
        <CompensationAmt>125548</CompensationAmt>
      </ContractorCompensationGrp>
      <CntrctRcvdGreaterThan100KCnt>1</CntrctRcvdGreaterThan100KCnt>
      <AllOtherContributionsAmt>333654</AllOtherContributionsAmt>
      <TotalContributionsAmt>333654</TotalContributionsAmt>
      <InvestmentIncomeGrp>
        <TotalRevenueColumnAmt>140054</TotalRevenueColumnAmt>
        <ExclusionAmt>140054</ExclusionAmt>
      </InvestmentIncomeGrp>
      <GrossAmountSalesAssetsGrp>
        <SecuritiesAmt>2399337</SecuritiesAmt>
      </GrossAmountSalesAssetsGrp>
      <LessCostOthBasisSalesExpnssGrp>
        <SecuritiesAmt>2013250</SecuritiesAmt>
      </LessCostOthBasisSalesExpnssGrp>
      <GainOrLossGrp>
        <SecuritiesAmt>386087</SecuritiesAmt>
      </GainOrLossGrp>
      <NetGainOrLossInvestmentsGrp>
        <TotalRevenueColumnAmt>386087</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>386087</RelatedOrExemptFuncIncomeAmt>
      </NetGainOrLossInvestmentsGrp>
      <TotalRevenueGrp>
        <TotalRevenueColumnAmt>859795</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>386087</RelatedOrExemptFuncIncomeAmt>
        <UnrelatedBusinessRevenueAmt>0</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>140054</ExclusionAmt>
      </TotalRevenueGrp>
      <InfoInScheduleOPartIXInd>X</InfoInScheduleOPartIXInd>
      <GrantsToDomesticOrgsGrp>
        <TotalAmt>224604</TotalAmt>
        <ProgramServicesAmt>224604</ProgramServicesAmt>
      </GrantsToDomesticOrgsGrp>
      <ForeignGrantsGrp>
        <TotalAmt>45538</TotalAmt>
        <ProgramServicesAmt>45538</ProgramServicesAmt>
      </ForeignGrantsGrp>
      <CompCurrentOfcrDirectorsGrp>
        <TotalAmt>20000</TotalAmt>
        <ProgramServicesAmt>16000</ProgramServicesAmt>
        <ManagementAndGeneralAmt>4000</ManagementAndGeneralAmt>
      </CompCurrentOfcrDirectorsGrp>
      <OtherSalariesAndWagesGrp>
        <TotalAmt>13172</TotalAmt>
        <ProgramServicesAmt>7139</ProgramServicesAmt>
        <ManagementAndGeneralAmt>3879</ManagementAndGeneralAmt>
        <FundraisingAmt>2154</FundraisingAmt>
      </OtherSalariesAndWagesGrp>
      <OtherEmployeeBenefitsGrp>
        <TotalAmt>9774</TotalAmt>
        <ProgramServicesAmt>6173</ProgramServicesAmt>
        <ManagementAndGeneralAmt>2718</ManagementAndGeneralAmt>
        <FundraisingAmt>883</FundraisingAmt>
      </OtherEmployeeBenefitsGrp>
      <PayrollTaxesGrp>
        <TotalAmt>2924</TotalAmt>
        <ProgramServicesAmt>1914</ProgramServicesAmt>
        <ManagementAndGeneralAmt>787</ManagementAndGeneralAmt>
        <FundraisingAmt>223</FundraisingAmt>
      </PayrollTaxesGrp>
      <FeesForServicesAccountingGrp>
        <TotalAmt>22138</TotalAmt>
        <ManagementAndGeneralAmt>22138</ManagementAndGeneralAmt>
      </FeesForServicesAccountingGrp>
      <FeesForSrvcInvstMgmntFeesGrp>
        <TotalAmt>125548</TotalAmt>
        <ManagementAndGeneralAmt>125548</ManagementAndGeneralAmt>
      </FeesForSrvcInvstMgmntFeesGrp>
      <FeesForServicesOtherGrp>
        <TotalAmt>87179</TotalAmt>
        <ProgramServicesAmt>87179</ProgramServicesAmt>
      </FeesForServicesOtherGrp>
      <AdvertisingGrp>
        <TotalAmt>2521</TotalAmt>
        <ProgramServicesAmt>2521</ProgramServicesAmt>
      </AdvertisingGrp>
      <OfficeExpensesGrp>
        <TotalAmt>895</TotalAmt>
        <ProgramServicesAmt>708</ProgramServicesAmt>
        <ManagementAndGeneralAmt>187</ManagementAndGeneralAmt>
      </OfficeExpensesGrp>
      <OccupancyGrp>
        <TotalAmt>17234</TotalAmt>
        <ProgramServicesAmt>16658</ProgramServicesAmt>
        <ManagementAndGeneralAmt>576</ManagementAndGeneralAmt>
      </OccupancyGrp>
      <ConferencesMeetingsGrp>
        <TotalAmt>3424</TotalAmt>
        <ProgramServicesAmt>3424</ProgramServicesAmt>
      </ConferencesMeetingsGrp>
      <DepreciationDepletionGrp>
        <TotalAmt>600</TotalAmt>
        <ProgramServicesAmt>600</ProgramServicesAmt>
      </DepreciationDepletionGrp>
      <InsuranceGrp>
        <TotalAmt>249</TotalAmt>
        <ProgramServicesAmt>187</ProgramServicesAmt>
        <ManagementAndGeneralAmt>62</ManagementAndGeneralAmt>
      </InsuranceGrp>
      <OtherExpensesGrp>
        <Desc>RESEARCH AND INFORMATIO</Desc>
        <TotalAmt>5468</TotalAmt>
        <ProgramServicesAmt>5468</ProgramServicesAmt>
      </OtherExpensesGrp>
      <TotalFunctionalExpensesGrp>
        <TotalAmt>581268</TotalAmt>
        <ProgramServicesAmt>418113</ProgramServicesAmt>
        <ManagementAndGeneralAmt>159895</ManagementAndGeneralAmt>
        <FundraisingAmt>3260</FundraisingAmt>
      </TotalFunctionalExpensesGrp>
      <CashNonInterestBearingGrp>
        <BOYAmt>372643</BOYAmt>
        <EOYAmt>690750</EOYAmt>
      </CashNonInterestBearingGrp>
      <SavingsAndTempCashInvstGrp>
        <BOYAmt>403309</BOYAmt>
        <EOYAmt>403362</EOYAmt>
      </SavingsAndTempCashInvstGrp>
      <AccountsReceivableGrp>
        <BOYAmt>11744</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </AccountsReceivableGrp>
      <PrepaidExpensesDefrdChargesGrp>
        <BOYAmt>2884</BOYAmt>
        <EOYAmt>4212</EOYAmt>
      </PrepaidExpensesDefrdChargesGrp>
      <LandBldgEquipCostOrOtherBssAmt>12396</LandBldgEquipCostOrOtherBssAmt>
      <LandBldgEquipAccumDeprecAmt>10296</LandBldgEquipAccumDeprecAmt>
      <LandBldgEquipBasisNetGrp>
        <BOYAmt>2700</BOYAmt>
        <EOYAmt>2100</EOYAmt>
      </LandBldgEquipBasisNetGrp>
      <InvestmentsPubTradedSecGrp>
        <BOYAmt>14214680</BOYAmt>
        <EOYAmt>10366590</EOYAmt>
      </InvestmentsPubTradedSecGrp>
      <OtherAssetsTotalGrp>
        <BOYAmt>520614</BOYAmt>
        <EOYAmt>408778</EOYAmt>
      </OtherAssetsTotalGrp>
      <TotalAssetsGrp>
        <BOYAmt>15528574</BOYAmt>
        <EOYAmt>11875792</EOYAmt>
      </TotalAssetsGrp>
      <AccountsPayableAccrExpnssGrp>
        <BOYAmt>6907</BOYAmt>
        <EOYAmt>72</EOYAmt>
      </AccountsPayableAccrExpnssGrp>
      <OtherLiabilitiesGrp>
        <BOYAmt>38111</BOYAmt>
        <EOYAmt>42392</EOYAmt>
      </OtherLiabilitiesGrp>
      <TotalLiabilitiesGrp>
        <BOYAmt>45018</BOYAmt>
        <EOYAmt>42464</EOYAmt>
      </TotalLiabilitiesGrp>
      <OrganizationFollowsFASB117Ind>X</OrganizationFollowsFASB117Ind>
      <NoDonorRestrictionNetAssetsGrp>
        <BOYAmt>14537017</BOYAmt>
        <EOYAmt>10943315</EOYAmt>
      </NoDonorRestrictionNetAssetsGrp>
      <DonorRestrictionNetAssetsGrp>
        <BOYAmt>946539</BOYAmt>
        <EOYAmt>890013</EOYAmt>
      </DonorRestrictionNetAssetsGrp>
      <TotalNetAssetsFundBalanceGrp>
        <BOYAmt>15483556</BOYAmt>
        <EOYAmt>11833328</EOYAmt>
      </TotalNetAssetsFundBalanceGrp>
      <TotLiabNetAssetsFundBalanceGrp>
        <BOYAmt>15528574</BOYAmt>
        <EOYAmt>11875792</EOYAmt>
      </TotLiabNetAssetsFundBalanceGrp>
      <InfoInScheduleOPartXIInd>X</InfoInScheduleOPartXIInd>
      <ReconcilationRevenueExpnssAmt>278527</ReconcilationRevenueExpnssAmt>
      <NetUnrlzdGainsLossesInvstAmt>-3832229</NetUnrlzdGainsLossesInvstAmt>
      <OtherChangesInNetAssetsAmt>-96526</OtherChangesInNetAssetsAmt>
      <InfoInScheduleOPartXIIInd>X</InfoInScheduleOPartXIIInd>
      <MethodOfAccountingAccrualInd>X</MethodOfAccountingAccrualInd>
      <AccountantCompileOrReviewInd>0</AccountantCompileOrReviewInd>
      <FSAuditedInd>1</FSAuditedInd>
      <FSAuditedBasisGrp>
        <ConsolAndSepBasisFinclStmtInd>X</ConsolAndSepBasisFinclStmtInd>
      </FSAuditedBasisGrp>
      <AuditCommitteeInd>1</AuditCommitteeInd>
      <FederalGrantAuditRequiredInd>0</FederalGrantAuditRequiredInd>
    </IRS990>
    <IRS990ScheduleA documentId="RetDoc1039100001">
      <PublicOrganization170Ind>X</PublicOrganization170Ind>
      <GiftsGrantsContriRcvd170Grp>
        <CurrentTaxYearMinus4YearsAmt>57870</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>136042</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>74498</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>69409</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>333654</CurrentTaxYearAmt>
        <TotalAmt>671473</TotalAmt>
      </GiftsGrantsContriRcvd170Grp>
      <TotalCalendarYear170Grp>
        <CurrentTaxYearMinus4YearsAmt>57870</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>136042</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>74498</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>69409</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>333654</CurrentTaxYearAmt>
        <TotalAmt>671473</TotalAmt>
      </TotalCalendarYear170Grp>
      <PublicSupportTotal170Amt>671473</PublicSupportTotal170Amt>
      <GrossInvestmentIncome170Grp>
        <CurrentTaxYearMinus4YearsAmt>162465</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>162080</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>141897</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>154090</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>140054</CurrentTaxYearAmt>
        <TotalAmt>760586</TotalAmt>
      </GrossInvestmentIncome170Grp>
      <OtherIncome170Grp>
        <CurrentTaxYearMinus3YearsAmt>15549</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus1YearAmt>8505</CurrentTaxYearMinus1YearAmt>
        <TotalAmt>24054</TotalAmt>
      </OtherIncome170Grp>
      <TotalSupportAmt>1456113</TotalSupportAmt>
      <PublicSupportCY170Pct>0.46110</PublicSupportCY170Pct>
      <PublicSupportPY170Pct>0.26690</PublicSupportPY170Pct>
      <ThirtyThrPctSuprtTestsCY170Ind>X</ThirtyThrPctSuprtTestsCY170Ind>
    </IRS990ScheduleA>
    <IRS990ScheduleB documentId="RetDoc1234500001">
      <ContributorInformationGrp>
        <ContributorNum>RESTRICTED</ContributorNum>
        <ContributorBusinessName>
          <BusinessNameLine1>RESTRICTED</BusinessNameLine1>
        </ContributorBusinessName>
        <ContributorUSAddress>
          <AddressLine1>RESTRICTED</AddressLine1>
          <AddressLine2>RESTRICTED</AddressLine2>
          <City>RESTRICTED</City>
          <State>RESTRICTED</State>
          <ZIPCode>RESTRICTED</ZIPCode>
        </ContributorUSAddress>
        <TotalContributionsAmt>RESTRICTED</TotalContributionsAmt>
      </ContributorInformationGrp>
    </IRS990ScheduleB>
    <IRS990ScheduleC documentId="RetDoc1039600001">
      <OrganizationBelongsAffltGrpInd referenceDocumentId="RetDoc2137600001">X</OrganizationBelongsAffltGrpInd>
      <TotalGrassrootsLobbyingGrp>
        <FilingOrganizationsTotalAmt>0</FilingOrganizationsTotalAmt>
        <AffiliatedGroupTotalAmt>15679</AffiliatedGroupTotalAmt>
      </TotalGrassrootsLobbyingGrp>
      <TotalDirectLobbyingGrp>
        <FilingOrganizationsTotalAmt>0</FilingOrganizationsTotalAmt>
        <AffiliatedGroupTotalAmt>6950</AffiliatedGroupTotalAmt>
      </TotalDirectLobbyingGrp>
      <TotalLobbyingExpendGrp>
        <AffiliatedGroupTotalAmt>22629</AffiliatedGroupTotalAmt>
      </TotalLobbyingExpendGrp>
      <OtherExemptPurposeExpendGrp>
        <FilingOrganizationsTotalAmt>581268</FilingOrganizationsTotalAmt>
        <AffiliatedGroupTotalAmt>2855106</AffiliatedGroupTotalAmt>
      </OtherExemptPurposeExpendGrp>
      <TotalExemptPurposeExpendGrp>
        <FilingOrganizationsTotalAmt>581268</FilingOrganizationsTotalAmt>
        <AffiliatedGroupTotalAmt>2877735</AffiliatedGroupTotalAmt>
      </TotalExemptPurposeExpendGrp>
      <LobbyingNontaxableAmountGrp>
        <FilingOrganizationsTotalAmt>112190</FilingOrganizationsTotalAmt>
        <AffiliatedGroupTotalAmt>293887</AffiliatedGroupTotalAmt>
      </LobbyingNontaxableAmountGrp>
      <GrassrootsNontaxableGrp>
        <FilingOrganizationsTotalAmt>28048</FilingOrganizationsTotalAmt>
        <AffiliatedGroupTotalAmt>73472</AffiliatedGroupTotalAmt>
      </GrassrootsNontaxableGrp>
      <TotLbbyngGrassrootMnsNonTxGrp>
        <FilingOrganizationsTotalAmt>0</FilingOrganizationsTotalAmt>
        <AffiliatedGroupTotalAmt>0</AffiliatedGroupTotalAmt>
      </TotLbbyngGrassrootMnsNonTxGrp>
      <TotLbbyExpendMnsLbbyngNonTxGrp>
        <FilingOrganizationsTotalAmt>0</FilingOrganizationsTotalAmt>
        <AffiliatedGroupTotalAmt>0</AffiliatedGroupTotalAmt>
      </TotLbbyExpendMnsLbbyngNonTxGrp>
      <AvgLobbyingNontaxableAmountGrp>
        <CurrentYearMinus2Amt>104056</CurrentYearMinus2Amt>
        <CurrentYearMinus1Amt>106057</CurrentYearMinus1Amt>
        <CurrentYearAmt>293887</CurrentYearAmt>
        <TotalAmt>504000</TotalAmt>
      </AvgLobbyingNontaxableAmountGrp>
      <LobbyingCeilingAmt>756000</LobbyingCeilingAmt>
      <AvgTotalLobbyingExpendGrp>
        <CurrentYearMinus2Amt>46</CurrentYearMinus2Amt>
        <CurrentYearMinus1Amt>90</CurrentYearMinus1Amt>
        <CurrentYearAmt>22629</CurrentYearAmt>
        <TotalAmt>22765</TotalAmt>
      </AvgTotalLobbyingExpendGrp>
      <AvgGrassrootsNontaxableGrp>
        <CurrentYearMinus2Amt>26014</CurrentYearMinus2Amt>
        <CurrentYearMinus1Amt>26514</CurrentYearMinus1Amt>
        <CurrentYearAmt>73472</CurrentYearAmt>
        <TotalAmt>126000</TotalAmt>
      </AvgGrassrootsNontaxableGrp>
      <GrassrootsCeilingAmt>189000</GrassrootsCeilingAmt>
      <AvgGrassrootsLobbyingExpendGrp>
        <CurrentYearAmt>15679</CurrentYearAmt>
        <TotalAmt>15679</TotalAmt>
      </AvgGrassrootsLobbyingExpendGrp>
    </IRS990ScheduleC>
    <IRS990ScheduleD documentId="RetDoc1040000001">
      <CYEndwmtFundGrp>
        <BeginningYearBalanceAmt>14214680</BeginningYearBalanceAmt>
        <InvestmentEarningsOrLossesAmt>-3448036</InvestmentEarningsOrLossesAmt>
        <OtherExpendituresAmt>400054</OtherExpendituresAmt>
        <EndYearBalanceAmt>10366590</EndYearBalanceAmt>
      </CYEndwmtFundGrp>
      <CYMinus1YrEndwmtFundGrp>
        <BeginningYearBalanceAmt>12674289</BeginningYearBalanceAmt>
        <InvestmentEarningsOrLossesAmt>1890391</InvestmentEarningsOrLossesAmt>
        <OtherExpendituresAmt>350000</OtherExpendituresAmt>
        <EndYearBalanceAmt>14214680</EndYearBalanceAmt>
      </CYMinus1YrEndwmtFundGrp>
      <CYMinus2YrEndwmtFundGrp>
        <BeginningYearBalanceAmt>10737802</BeginningYearBalanceAmt>
        <InvestmentEarningsOrLossesAmt>2311583</InvestmentEarningsOrLossesAmt>
        <OtherExpendituresAmt>375096</OtherExpendituresAmt>
        <EndYearBalanceAmt>12674289</EndYearBalanceAmt>
      </CYMinus2YrEndwmtFundGrp>
      <CYMinus3YrEndwmtFundGrp>
        <BeginningYearBalanceAmt>9074310</BeginningYearBalanceAmt>
        <InvestmentEarningsOrLossesAmt>2033864</InvestmentEarningsOrLossesAmt>
        <OtherExpendituresAmt>370372</OtherExpendituresAmt>
        <EndYearBalanceAmt>10737802</EndYearBalanceAmt>
      </CYMinus3YrEndwmtFundGrp>
      <CYMinus4YrEndwmtFundGrp>
        <BeginningYearBalanceAmt>9615924</BeginningYearBalanceAmt>
        <InvestmentEarningsOrLossesAmt>-166192</InvestmentEarningsOrLossesAmt>
        <OtherExpendituresAmt>375422</OtherExpendituresAmt>
        <EndYearBalanceAmt>9074310</EndYearBalanceAmt>
      </CYMinus4YrEndwmtFundGrp>
      <BoardDesignatedBalanceEOYPct>1.00000</BoardDesignatedBalanceEOYPct>
      <PrmnntEndowmentBalanceEOYPct>0.00000</PrmnntEndowmentBalanceEOYPct>
      <TermEndowmentBalanceEOYPct>0.00000</TermEndowmentBalanceEOYPct>
      <EndowmentsHeldUnrelatedOrgInd>1</EndowmentsHeldUnrelatedOrgInd>
      <EndowmentsHeldRelatedOrgInd>0</EndowmentsHeldRelatedOrgInd>
      <EquipmentGrp>
        <OtherCostOrOtherBasisAmt>12396</OtherCostOrOtherBasisAmt>
        <DepreciationAmt>10296</DepreciationAmt>
        <BookValueAmt>2100</BookValueAmt>
      </EquipmentGrp>
      <TotalBookValueLandBuildingsAmt>2100</TotalBookValueLandBuildingsAmt>
      <OtherLiabilitiesOrgGrp>
        <Desc>PAYABLE TO AFFILIATE</Desc>
        <Amt>18940</Amt>
      </OtherLiabilitiesOrgGrp>
      <OtherLiabilitiesOrgGrp>
        <Desc>LEASE OBLIGATIONS</Desc>
        <Amt>23452</Amt>
      </OtherLiabilitiesOrgGrp>
      <TotalLiabilityAmt>42392</TotalLiabilityAmt>
      <FootnoteTextInd>X</FootnoteTextInd>
      <TotalRevEtcAuditedFinclStmtAmt>-3194508</TotalRevEtcAuditedFinclStmtAmt>
      <NetUnrealizedGainsInvstAmt>-3832229</NetUnrealizedGainsInvstAmt>
      <OtherRevenueAmt>-222074</OtherRevenueAmt>
      <RevenueNotReportedAmt>-4054303</RevenueNotReportedAmt>
      <RevenueSubtotalAmt>859795</RevenueSubtotalAmt>
      <RevenueNotReportedFinclStmtAmt>0</RevenueNotReportedFinclStmtAmt>
      <TotalRevenuePerForm990Amt>859795</TotalRevenuePerForm990Amt>
      <TotExpnsEtcAuditedFinclStmtAmt>455720</TotExpnsEtcAuditedFinclStmtAmt>
      <ExpensesNotReportedAmt>0</ExpensesNotReportedAmt>
      <ExpensesSubtotalAmt>455720</ExpensesSubtotalAmt>
      <InvestmentExpensesNotIncld2Amt>125548</InvestmentExpensesNotIncld2Amt>
      <ExpensesNotRptFinclStmtAmt>125548</ExpensesNotRptFinclStmtAmt>
      <TotalExpensesPerForm990Amt>581268</TotalExpensesPerForm990Amt>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART V, LINE 4:</FormAndLineReferenceDesc>
        <ExplanationTxt>THE ORGANIZATION'S QUASI-ENDOWMENT FUNDS FUND THE VARIOUS ACTIVITIES OF ARDF. THIS INCLUDES FUNDING RESEARCH PROJECTS THAT DEVELOP NON-ANIMAL ALTERNATIVES TO TRADITIONAL ANIMAL EXPERIMENTS AND SPONSORSHIP OF SCIENTIFIC MEETINGS PROMOTING ALTERNATIVES.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART X, LINE 2:</FormAndLineReferenceDesc>
        <ExplanationTxt>MANAGEMENT BELIEVES THAT IT HAS APPROPRIATE SUPPORT FOR ANY TAX PROVISIONS TAKEN, AND AS SUCH, THE FOUNDATION DOES NOT HAVE ANY UNCERTIAN TAX POSITIONS THAT ARE MATERIAL TO THE FINANCIAL STATEMENTS.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART XI, LINE 2D - OTHER ADJUSTMENTS:</FormAndLineReferenceDesc>
        <ExplanationTxt>UNREALIZED LOSS ON BENEFICIAL INTEREST IN PERPETUAL TRUST -96,526. INVESTMENT FEES -125,548.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleD>
    <IRS990ScheduleF documentId="RetDoc1040500001">
      <GrantRecordsMaintainedInd>1</GrantRecordsMaintainedInd>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>EUROPE (INCLUDING ICELAND &amp; GREENLAND)</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>0</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>PROGRAM SERVICES</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>RESEARCH GRANTS</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>45538</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>EUROPE (INCLUDING ICELAND &amp; GREENLAND)</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>1</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>PROGRAM SERVICES</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>GRANT PROGRAM MANAGEMENT</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>78720</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <SubtotalOfficesCnt>0</SubtotalOfficesCnt>
      <SubtotalEmployeesCnt>1</SubtotalEmployeesCnt>
      <ContinuationTotalOfficeCnt>0</ContinuationTotalOfficeCnt>
      <ContinuationTotalEmployeeCnt>0</ContinuationTotalEmployeeCnt>
      <TotalOfficeCnt>0</TotalOfficeCnt>
      <TotalEmployeeCnt>1</TotalEmployeeCnt>
      <SubtotalSpentAmt>124258</SubtotalSpentAmt>
      <ContinuationSpentAmt>0</ContinuationSpentAmt>
      <TotalSpentAmt>124258</TotalSpentAmt>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>EUROPE (INCLUDING ICELAND &amp; GREENLAND)</RegionTxt>
        <PurposeOfGrantTxt>DR. CRISTINA SCIELZO RESEARCH GRANT - 3D BIOPRINTING AND CELL CULTURE FOR CHRONIC LYMPHOCYTIC LEUKEMIA RESEARCH</PurposeOfGrantTxt>
        <CashGrantAmt>40000</CashGrantAmt>
        <MannerOfCashDisbursementTxt>WIRE TRANSFER</MannerOfCashDisbursementTxt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>EUROPE (INCLUDING ICELAND &amp; GREENLAND)</RegionTxt>
        <PurposeOfGrantTxt>SPONSORSHIP - SCIENTIFIC MEETING ON IN VITRO METHODS</PurposeOfGrantTxt>
        <CashGrantAmt>5538</CashGrantAmt>
        <MannerOfCashDisbursementTxt>WIRE TRANSFER</MannerOfCashDisbursementTxt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
      </GrantsToOrgOutsideUSGrp>
      <TransferToForeignCorpInd>0</TransferToForeignCorpInd>
      <InterestInForeignTrustInd>0</InterestInForeignTrustInd>
      <ForeignCorpOwnershipInd>0</ForeignCorpOwnershipInd>
      <PassiveForeignInvestmestCoInd>0</PassiveForeignInvestmestCoInd>
      <ForeignPartnershipInd>0</ForeignPartnershipInd>
      <BoycottCountriesInd>0</BoycottCountriesInd>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART I, LINE 2:</FormAndLineReferenceDesc>
        <ExplanationTxt>PROGRESS REPORTS FOR RESEARCH GRANTS ARE REQUIRED AFTER 8 MONTHS AND THE FINAL REPORT IS DUE WHEN THE SUPPORTED PROGRAM IS COMPLETE. ANY UNUSED FUNDS MUST BE RETURNED OR USED FOR APPROVED PURPOSES ONLY.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART III ACCOUNTING METHOD:</FormAndLineReferenceDesc>
      </SupplementalInformationDetail>
    </IRS990ScheduleF>
    <IRS990ScheduleI documentId="RetDoc1041900001">
      <GrantRecordsMaintainedInd>1</GrantRecordsMaintainedInd>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>ALBERT EINSTEIN COLLEGE OF MEDICINE</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1300 MORRIS PARK AVENUE BELFER</AddressLine1Txt>
          <AddressLine2Txt>BUILDING - 3RD FLOOR</AddressLine2Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10461</ZIPCd>
        </USAddress>
        <RecipientEIN>830621846</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>40000</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>DR. EUGEN DHIMOLEA RESEARCH GRANT - 3D ORGANOID MODEL FOR CANCER RESEARCH</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>CHILDREN'S HOSPITAL LOS ANGELES</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>4650 SUNSET BOULEVARD MAIL STOP 97</AddressLine1Txt>
          <CityNm>LOS ANGELES</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>90027</ZIPCd>
        </USAddress>
        <RecipientEIN>951690977</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>40000</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>DR. MEENAKSHI UPRETI RESEARCH GRANT - 3D IN VITRO MODEL FOR PEDIATRIC TUMORS</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>INSTITUTE FOR IN VITRO SCIENCES INC</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>30 W WATKINS MILL ROAD SUITE 100</AddressLine1Txt>
          <CityNm>GAITHERSBURG</CityNm>
          <StateAbbreviationCd>MD</StateAbbreviationCd>
          <ZIPCd>20878</ZIPCd>
        </USAddress>
        <RecipientEIN>522029668</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>12500</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>DESIGNATED GRANTEE FOR CAVE AWARD TO DR. DANIEL BAGLEY AND EVENT SPONSORSHIP</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>615 NORTH WOLFE STREET</AddressLine1Txt>
          <CityNm>BALTIMORE</CityNm>
          <StateAbbreviationCd>MD</StateAbbreviationCd>
          <ZIPCd>21205</ZIPCd>
        </USAddress>
        <RecipientEIN>520595110</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>10000</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>SPONSORSHIP - MPS (MICROPHYSIOLOGICAL SYSTEMS) WORLD SUMMIT SCIENTIFIC MEETING</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>PACE UNIVERSITY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>41 PARK ROW</AddressLine1Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10038</ZIPCd>
        </USAddress>
        <RecipientEIN>135562314</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>40000</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>DR. NIGEL YARLETT RESEARCH GRANT - IN VITRO PARASITE CULTURE TO REPLACE ANIMALS</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>104 AIRPORT DRIVE SUITE 2200</AddressLine1Txt>
          <CityNm>CHAPEL HILL</CityNm>
          <StateAbbreviationCd>NC</StateAbbreviationCd>
          <ZIPCd>27599</ZIPCd>
        </USAddress>
        <RecipientEIN>566001393</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>39823</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>DR. EUGENE MURATOV RESEARCH GRANT - COMPUTATIONAL MODEL FOR ECOLOGICAL RISK ASSESSMENT</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNIVERSITY OF PITTSBURGH</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>300 MURDOCH BUILDING 3420 FORBES</AddressLine1Txt>
          <AddressLine2Txt>AVENUE</AddressLine2Txt>
          <CityNm>PITTSBURGH</CityNm>
          <StateAbbreviationCd>PA</StateAbbreviationCd>
          <ZIPCd>15260</ZIPCd>
        </USAddress>
        <RecipientEIN>250965591</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>40000</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>DR. HANG LIN RESEARCH GRANT - TRANSGENIC "MINIJOINT" ON A CHIP FOR OSTEOARTHRITIS RESEARCH</PurposeOfGrantTxt>
      </RecipientTable>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART I, LINE 2:</FormAndLineReferenceDesc>
        <ExplanationTxt>PROGRESS REPORTS FOR RESEARCH GRANTS ARE REQUIRED AFTER 8 MONTHS AND A FINAL REPORT IS DUE WHEN THE SUPPORTED PROGRAM IS COMPLETE. ANY UNUSED FUNDS MUST BE RETURNED OR USED FOR APPROVED PURPOSES ONLY.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleI>
    <IRS990ScheduleO documentId="RetDoc1044400001">
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART V, LINE 24 AND PART IX</FormAndLineReferenceDesc>
        <ExplanationTxt>SALARIES REFLECTED ON THE STATEMENT OF FUNCTIONAL EXPENSES ARE ALLOCATIONS OF SALARIES AS A PORTION OF MANAGEMENT EXPENSES THAT THE ORGANIZATION PAYS TO ITS AFFILATE, THE AMERICAN ANTI-VIVISECTION SOCIETY. NOTE THAT THE ONE EMPLOYEE, SUE LEARY, IS PAID BY A COMMON PAYMASTER. THE ORGANIZATION'S AFFILIATE AMERICAN ANTI-VIVISECTION SOCIETY. THERE IS NO W-3 REPORTED FOR THIS ENTITY; ALL FILING REQUIREMENTS ARE MET THROUGH THE AFFILIATE AS MENTIONED.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, SECTION B, LINE 11B</FormAndLineReferenceDesc>
        <ExplanationTxt>THE PRESIDENT, TREASURER AND BOARD OF DIRECTORS REVIEW THE FORM 990 BEFORE IT IS FILED.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, SECTION B, LINE 12C</FormAndLineReferenceDesc>
        <ExplanationTxt>THE ORGANIZATION FOLLOWS THE POLICIES OF ITS AFFILIATE, AMERICAN ANTI-VIVISECTION SOCIETY (AAVS), WITH WHICH IT SHARES ITS BOARD OF MANAGERS. THE BOARD OF MANAGERS MONITORS AND ENFORCES COMPLIANCE WITH THE CONFLICT OF INTEREST POLICIES (AS DETERMINED BY AAVS). ANNUAL DISCLOSURE FORMS ARE COLLECTED FROM EACH BOARD MEMBER AND REVIEWED BY THE PRESIDENT WHO ENSURES THAT MEMBERS RECUSE THEMSELVES FROM VOTING ON ANY MATTERS IN WHICH THEY MAY HAVE A DUAL INTEREST. THE BOARD OF MANAGERS, EXCLUDING THE PRESIDENT, ENSURES THAT THE PRESIDENT RECSUES HERSELF IN CASE OF A POTENTIAL CONFLICT OF INTEREST. THE CONFLICT OF INTEREST POLICY EXPLICITLY DEEMS FAMILY AND BUSINESS RELATIONSHIPS TO HAVE POTENTIAL FOR CONFLICTS AND REQUESTS DETAILED INFORMATION ON ANY SUCH RELATIONSHIPS AS PART OF THE ANNUAL CONFLICT OF INTEREST POLICY PROCESS.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, SECTION B, LINE 15A</FormAndLineReferenceDesc>
        <ExplanationTxt>THE ORGANIZATION'S COMPENSATION POLICIES ARE DICTATED BY ITS AFFILIATE, AMERICAN ANTI-VIVISECTION SOCIETY (AAVS) WITH WHOM IT SHARES A BOARD OF MANAGERS. THE BOARD OF MANAGERS DETERMINES COMPENSATION OF THE PRESIDENT BY COMPARING WITH COMPENSATION OF EQUIVALENT POSITIONS USING PUBLICLY AVAILABLE DATA. NOTE THE PRESIDENT'S SALARY IS DETERMINED BY AAVS BUT IS REPORTED ON BOTH RETURNS. DECISIONS ARE RECORDED IN BOARD MINUTES AND MATERIALS.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, SECTION C, LINE 19</FormAndLineReferenceDesc>
        <ExplanationTxt>GOVERNING DOCUMENTS, THE CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART IX, LINE 11G</FormAndLineReferenceDesc>
        <ExplanationTxt>SUBCONTRACTED LABOR: PROGRAM SERVICE EXPENSES 87,179. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 87,179.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART XI, LINE 9:</FormAndLineReferenceDesc>
        <ExplanationTxt>UNREALIZED LOSS ON BENEFICIAL INTEREST IN PERPETUAL TRUST -96,526.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART XII, LINE 2C:</FormAndLineReferenceDesc>
        <ExplanationTxt>THERE WAS NO CHANGE IN THE AUDIT OVERSIGHT PROCESS FROM THE PRIOR YEAR.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleO>
    <IRS990ScheduleR documentId="RetDoc1043400001">
      <IdRelatedTaxExemptOrgGrp>
        <DisregardedEntityName>
          <BusinessNameLine1Txt>AMERICAN ANTI-VIVISECTION SOCIETY</BusinessNameLine1Txt>
        </DisregardedEntityName>
        <USAddress>
          <AddressLine1Txt>801 OLD YORK ROAD NOBLE PLAZA SUITE</AddressLine1Txt>
          <CityNm>JENKINTOWN</CityNm>
          <StateAbbreviationCd>PA</StateAbbreviationCd>
          <ZIPCd>19046</ZIPCd>
        </USAddress>
        <EIN>230341990</EIN>
        <PrimaryActivitiesTxt>EDUCATE THE PUBLIC ON PROBLEMS OF ANIMAL EXPERIMENTATION</PrimaryActivitiesTxt>
        <LegalDomicileStateCd>PA</LegalDomicileStateCd>
        <ExemptCodeSectionTxt>501(C)(3)</ExemptCodeSectionTxt>
        <PublicCharityStatusTxt>LINE 7</PublicCharityStatusTxt>
        <DirectControllingEntityName>
          <BusinessNameLine1Txt>NONE</BusinessNameLine1Txt>
        </DirectControllingEntityName>
        <ControlledOrganizationInd>0</ControlledOrganizationInd>
      </IdRelatedTaxExemptOrgGrp>
      <ReceiptOfIntAnntsRntsRyltsInd>0</ReceiptOfIntAnntsRntsRyltsInd>
      <GiftGrntOrCapContriToOthOrgInd>0</GiftGrntOrCapContriToOthOrgInd>
      <GiftGrntCapContriFromOthOrgInd>0</GiftGrntCapContriFromOthOrgInd>
      <LoansOrGuaranteesToOtherOrgInd>0</LoansOrGuaranteesToOtherOrgInd>
      <LoansOrGuaranteesFromOthOrgInd>1</LoansOrGuaranteesFromOthOrgInd>
      <DivRelatedOrganizationInd>0</DivRelatedOrganizationInd>
      <AssetSaleToOtherOrgInd>0</AssetSaleToOtherOrgInd>
      <AssetPurchaseFromOtherOrgInd>0</AssetPurchaseFromOtherOrgInd>
      <AssetExchangeInd>0</AssetExchangeInd>
      <RentalOfFacilitiesToOthOrgInd>0</RentalOfFacilitiesToOthOrgInd>
      <RentalOfFcltsFromOthOrgInd>0</RentalOfFcltsFromOthOrgInd>
      <PerformOfServicesForOthOrgInd>0</PerformOfServicesForOthOrgInd>
      <PerformOfServicesByOtherOrgInd>1</PerformOfServicesByOtherOrgInd>
      <SharingOfFacilitiesInd>1</SharingOfFacilitiesInd>
      <PaidEmployeesSharingInd>1</PaidEmployeesSharingInd>
      <ReimbursementPaidToOtherOrgInd>1</ReimbursementPaidToOtherOrgInd>
      <ReimbursementPaidByOtherOrgInd>0</ReimbursementPaidByOtherOrgInd>
      <TransferToOtherOrgInd>0</TransferToOtherOrgInd>
      <TransferFromOtherOrgInd>0</TransferFromOtherOrgInd>
    </IRS990ScheduleR>
    <AffiliatedGroupSchedule documentId="RetDoc2137600001">
      <AffiliatedScheduleGrp>
        <BusinessName>
          <BusinessNameLine1Txt>ALTERNATIVES RESEARCH AND DEVELOPMENT FOUNDATION</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>801 OLD YORK ROAD SUITE 218</AddressLine1Txt>
          <CityNm>JENKINTOWN</CityNm>
          <StateAbbreviationCd>PA</StateAbbreviationCd>
          <ZIPCd>19046</ZIPCd>
        </USAddress>
        <EIN>232740843</EIN>
        <TotalGrassrootsLobbyAmt>0</TotalGrassrootsLobbyAmt>
        <TotalDirectLobbyAmt>0</TotalDirectLobbyAmt>
        <TotalLobbyExpenditureAmt>0</TotalLobbyExpenditureAmt>
        <OtherExemptPurposeExpendAmt>581268</OtherExemptPurposeExpendAmt>
        <TotalExemptPurposeExpendAmt>581268</TotalExemptPurposeExpendAmt>
        <LobbyNontxAmt>112190</LobbyNontxAmt>
        <GrassrootsNontxAmt>28048</GrassrootsNontxAmt>
        <TotalLobbyGrssrootMnsNontxAmt>0</TotalLobbyGrssrootMnsNontxAmt>
        <TotLbbyExpendMnsLobbyNontxAmt>0</TotLbbyExpendMnsLobbyNontxAmt>
        <ShareExcessLobbyExpendAmt>0</ShareExcessLobbyExpendAmt>
      </AffiliatedScheduleGrp>
      <AffiliatedScheduleGrp>
        <BusinessName>
          <BusinessNameLine1Txt>AMERICAN ANTI-VIVISECTION SOCIETY INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>801 OLD YORK ROAD SUITE 204</AddressLine1Txt>
          <CityNm>JENKINTOWN</CityNm>
          <StateAbbreviationCd>PA</StateAbbreviationCd>
          <ZIPCd>19046</ZIPCd>
        </USAddress>
        <EIN>230341990</EIN>
        <TotalGrassrootsLobbyAmt>15679</TotalGrassrootsLobbyAmt>
        <TotalDirectLobbyAmt>6950</TotalDirectLobbyAmt>
        <TotalLobbyExpenditureAmt>22629</TotalLobbyExpenditureAmt>
        <OtherExemptPurposeExpendAmt>2855106</OtherExemptPurposeExpendAmt>
        <TotalExemptPurposeExpendAmt>2877735</TotalExemptPurposeExpendAmt>
        <LobbyNontxAmt>293887</LobbyNontxAmt>
        <GrassrootsNontxAmt>73472</GrassrootsNontxAmt>
        <TotalLobbyGrssrootMnsNontxAmt>0</TotalLobbyGrssrootMnsNontxAmt>
        <TotLbbyExpendMnsLobbyNontxAmt>0</TotLbbyExpendMnsLobbyNontxAmt>
        <ShareExcessLobbyExpendAmt>0</ShareExcessLobbyExpendAmt>
      </AffiliatedScheduleGrp>
    </AffiliatedGroupSchedule>
  </ReturnData>
</Return>
